Sebelipase Alfa

證據等級: L5

預測適應症: 10 個

Using the evidence pack, I'm presenting the drug's most evidence-backed predicted indication (Cholesteryl Ester Storage Disease, rank 4) rather than the top TxGNN-score hit (Scheie syndrome, rank 1), because the pack's own repurposing_rationale flags ranks 1–3 and 6–10 as mechanistically unrelated with zero supporting evidence — using them as the headline would misrepresent the actual signal. This is noted explicitly in the report below.

Sebelipase Alfa: From Lysosomal Acid Lipase Deficiency to Cholesteryl Ester Storage Disease

One-Sentence Summary

Sebelipase alfa is a recombinant human lysosomal acid lipase (rhLAL) enzyme replacement therapy for Lysosomal Acid Lipase Deficiency (LAL-D); Fimea/Finland licensing data on the original indication is unavailable in this evidence pack (the product is not marketed in Finland). Among 10 TxGNN-predicted indications, Cholesteryl Ester Storage Disease (CESD) — the late-onset phenotype of LAL-D — shows by far the strongest evidentiary support, with 9 clinical trials (including a completed placebo-controlled Phase 3 RCT) and 19 publications. The other 9 TxGNN-ranked candidates, including the highest raw-score hit (Scheie syndrome), have no mechanistic link to LAL and zero supporting trials or literature.

Quick Overview

Item	Content
Original Indication	Not available from Fimea (product not marketed in Finland; no license records). Per supporting literature in this pack, the drug's established indication is Lysosomal Acid Lipase Deficiency (LAL-D)
Predicted New Indication	Cholesteryl Ester Storage Disease (CESD)
TxGNN Prediction Score	99.72% (rank 4 of candidate set)
Evidence Level	L1
Finland Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action text is not available in structured form (DrugBank field flagged as a data gap). Based on the supporting literature in this pack, sebelipase alfa is a recombinant human lysosomal acid lipase (rhLAL) administered by intravenous infusion, which directly replaces the enzyme activity missing in LAL-D.

CESD is caused by biallelic LIPA mutations that reduce (but do not abolish) LAL enzyme activity — the same enzyme sebelipase alfa replaces. This is not a speculative cross-mechanism repurposing hypothesis; it is a direct enzyme-substrate match, which is why the evidence base is so much stronger here than for the model's other candidates. The pivotal Phase 3 ARISE trial (NCT01757184) — a randomized, placebo-controlled study in 66 patients with LAL-D/CESD — underpinned global regulatory approvals, and is corroborated by multiple Phase 1/2 dose-finding, long-term extension, and expanded-access studies in the same population.

By contrast, the model's top raw-score candidates — Scheie syndrome, Hurler syndrome, growth hormone insensitivity syndrome with immune dysregulation, Gaucher disease, lysosomal storage disease with skeletal involvement, autosomal ichthyosis syndrome, Tay-Sachs disease, and benign adrenal neoplasm — each involve a different, unrelated enzyme or pathway (e.g., alpha-L-iduronidase in Scheie/Hurler, glucocerebrosidase in Gaucher, hexosaminidase A in Tay-Sachs). These appear to reflect TxGNN's embedding-level similarity across "lysosomal storage disease" phenotypes rather than a true target match, and none returned any clinical trial or literature hits in this evidence pack. They are scored L5/Hold and are not evaluated further here.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01757184	Phase 3	Completed	66	ARISE study: randomized, placebo-controlled trial of sebelipase alfa (1 mg/kg IV every other week) in late-onset LAL-D/CESD; pivotal trial supporting global approval
NCT01371825	Phase 2/3	Completed	9	Open-label, dose-escalation study in children with growth failure due to LAL-D; weekly infusions for up to 5 years
NCT02112994	Phase 2	Completed	31	Multi-center, open-label study evaluating safety and efficacy in a broad LAL-D population
NCT01307098	Phase 1/2	Completed	9	First-in-human dose-escalation study (LAL-CL01) in adults with liver dysfunction due to LAL-D; supports dosing and safety
NCT01488097	Phase 2	Completed	8	Long-term extension of LAL-CL01; evaluated long-term safety and tolerability in adults with liver dysfunction
NCT02193867	Phase 2	Terminated	10	Once-weekly infusions in infants with rapidly progressive LAL-D (Wolman phenotype); study terminated
NCT02376751	N/A	No longer available	N/A	Expanded access protocol providing sebelipase alfa to LAL-D patients prior to commercial availability
NCT02926872	N/A	Terminated	22	DETECT: pediatric screening study for LAL-D as an underlying cause of abnormal liver tests (diagnostic, not treatment)
NCT04532047	Phase 1	Recruiting	10	PEARL: basket trial of in-utero enzyme replacement therapy across multiple lysosomal storage disorders; not CESD-specific, indirect relevance

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34774639	2022	RCT	Journal of Hepatology	Final results of the Phase 3 ARISE study; confirms efficacy and safety of sebelipase alfa in children ≥4 years and adults with LAL-D
35442238	2022	Cohort	J Pediatr Gastroenterol Nutr	Single-arm, open-label study (NCT02112994) evaluating long-term efficacy and safety in children and adults
29628368	2018	Cohort	J Clin Lipidol	Sebelipase alfa improves atherogenic cholesterol biomarkers over 52 weeks in the Phase 3 ARISE population
23348766	2013	Cohort	Hepatology	First human study (LAL-CL01) of recombinant human LAL; clinical effect and safety profile in CESD patients
24993530	2014	Cohort	Journal of Hepatology	52 weeks of sebelipase alfa reduces serum transaminases and liver volume, improves serum lipids in LAL-D
40781810	2025	Registry	Liver International	International registry data showing sebelipase alfa improves aminotransferase levels vs. untreated LAL-D patients
32103901	2020	Review	Drug Des Devel Ther	Review of therapeutic options for LAL deficiency, covering both Wolman disease and CESD subtypes
34664536	2022	Review	Expert Opin Drug Saf	Safety review of sebelipase alfa across early- and late-onset LAL-D phenotypes
26452566	2015	Review	Drugs	"Sebelipase alfa: first global approval" — regulatory and mechanistic overview
41357559	2025	Case report	ACG Case Rep J	Case of late-onset CESD presenting as hepatic steatosis/cirrhosis, confirmed LIPA mutation, treated with sebelipase alfa

Finland Market Information

No marketing authorization for sebelipase alfa is currently registered with Fimea — the product is not marketed in Finland (0 authorizations on file).

Safety Considerations

Please refer to the package insert for safety information. (No structured warnings, contraindications, or drug-interaction data are currently available for this product — see data gap DG001, flagged as blocking.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Sebelipase alfa's mechanism directly addresses the enzymatic deficiency underlying CESD, and this is supported by a completed placebo-controlled Phase 3 RCT (ARISE, NCT01757184) plus multiple earlier-phase and long-term studies in the same LAL-D population — evidence is substantially stronger than for any of the other 9 TxGNN-ranked candidates. However, the product is not marketed in Finland and core safety labeling (warnings/contraindications) is a blocking data gap.

To proceed, the following is needed:

Fimea/EU SmPC package insert to close the blocking safety data gap (DG001)
DrugBank mechanism-of-action detail to close DG002
Confirmation of whether CESD/Wolman disease should be framed as an already-approved indication elsewhere (EMA/FDA) rather than a novel repurposing candidate for this market
Finland market access feasibility assessment given ultra-rare disease status
No further action needed on the remaining 8 TxGNN-ranked candidates (Scheie syndrome, Hurler syndrome, growth hormone insensitivity syndrome with immune dysregulation, Gaucher disease, lysosomal storage disease with skeletal involvement, autosomal ichthyosis syndrome, Tay-Sachs disease, benign adrenal neoplasm) — Hold, no mechanistic or evidentiary support
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.